Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,881 total articles
PUIG BRANDS S.A. U/ADS (PUGBY) is a high-conviction long idea. At $9.91, the stock trades with technical momentum, limited observable short coverage, and is being priced like a conservatively valued luxury compounder despite reported revenue north of €5 billion in 2025. This trade targets a re-rating toward a mid-teens multiple over a mid-term hori…
Netflix trades at a reasonable multiple versus its recent premium and has cash flow and profitability to fund AI-driven improvements across recommendation, ad products, and content production. We prefer a tactical long: entry $77.60, stop $71.00, primary target $115.00 (180 trading days) with an interim target of $95.00 (45 trading days).
Novo Nordisk's market value of roughly $226.9B is not yet reflecting the steady cash generation and durable franchise in diabetes and obesity care. Technical momentum and low short interest days-to-cover make a mid-term long trade attractive from current levels. Entry $50.43, target $65.00, stop $45.00 — horizon: mid term (45 trading days).
ProQR's AX-0810 program targeting NTCP appears to have delivered human target engagement consistent with the Axiomer mechanism. With a cash runway into mid-2027, a tightened short interest profile, bullish technicals and a modest $241M market cap, the risk/reward favors a tactical long aimed at a re-rating toward the 52-week high.
MercadoLibre is trading well below its 52-week high after margin compression and higher loan-loss provisions, but the company’s scale, 49% revenue growth, and $11.8B in free cash flow create a favorable asymmetric risk-reward for a long trade. This idea targets a rotation back into growth over the next 180 trading days with a clear entry at current…
<p>Broadcom is trading well below its early-June peak despite fundamentals that argue for continued multiple expansion and outsized AI-related revenue growth. With $32.8B in free cash flow, a $1.71T market cap, and ROE above 33%, AVGO is a high-quality franchise that looks poised for a renewed leg up as hyperscalers and sovereign AI initiatives acc…
Vince has turned last year's losses into profitability, with Direct-to-Consumer growth, improved gross margins and a sub-10 P/E. The setup looks attractive for a mid-term swing trade, but limited cash, wholesale sensitivity and fashion-cycle risk argue for a disciplined entry and stop.
We like TKMS on the view that Europe’s naval modernization and rising defense budgets create multi-year, visible revenue for shipbuilders. Execution risk remains, but current setup offers asymmetric upside through contract awards and margin recovery. Trade plan: buy at $10.50, target $13.50, stop $8.75, horizon 180 trading days.
Allogene Therapeutics is an asymmetric bet: a $718M market cap, recent $175M equity raise and arbitration wins give the company runway and clearer rights to assets. Clinical signals (ALLO-316) and a growing CAR-T market create a plausible path to a multi-fold re-rating — but the trade is high-risk and needs a tight stop.
Lumentum (LITE) has pulled back from its May highs but remains squarely in the AI and hyperscaler optical supply chain. Fundamentals show strong profitability but extreme valuation and thin free cash flow relative to market cap. This trade targets a rebound to prior resistance while protecting capital with a nearby stop - a mid-term swing play with…
Affirm (AFRM) looks positioned for more upside over the next 11-45 trading days. Fundamentals show healthy free cash flow and a strong liquidity profile, technical momentum is bullish, and macro-friendly catalysts (Prime Day, easing rate pressure) could re-accelerate merchant adoption. This trade idea lays out an entry at $85.00, target at $100.00 …
Willdan (WLDN) is a small-cap consultant focused on energy and municipal engineering that continues to grow revenue and earnings while generating healthy free cash flow. The stock has pulled back into oversold territory; a disciplined long trade captures upside toward a valuation re-rating while limiting downside with a clear stop.
Once Upon a Farm's proprietary cold-chain cooler program turns shelf distribution into a semi-recurring revenue stream and creates a tangible moat for a fast-growing baby-food brand. With LTM revenue near $202M, 40-44% gross margins and a cooler footprint that already produces meaningful per-unit sales, the stock is a growth story trading at a sens…
Leonardo DRS is well positioned to benefit from elevated spending on radar, electronic warfare, and counter-drone systems. We recommend a tactical long starting at $24.50 with a target of $36.00 and a stop at $19.00 over a mid-term horizon (45 trading days).
American Shared Hospital Services (AMS) is a microcap provider of radiosurgery and radiation therapy leasing and services trading at a market cap of about $9.9M and a P/S of 0.34. With accelerating service revenue, attractive valuation metrics (EV/EBITDA ~5.7), and recent operational hires, a disciplined long trade targets a re-rating toward prior …
US Foods (USFD) is trading near its 52-week high after a run of market-share gains and improving profitability. The company is generating strong free cash flow and has reported double-digit EBITDA and EPS growth, supporting a tactical long. The setup favors a swing trade on continued share gains, but elevated valuation, leverage and overbought tech…
Valterra Platinum has just emerged as a standalone tolling-and-refining platform exposed to rising PGM tightness. With auto emissions rules and hydrogen fuel-cell demand lifting platinum and palladium support, Valterra's fee-for-service model should generate cash flow with limited capital intensity. This is a mid-term trade: buy on the early sign o…
PrimeEnergy trades at roughly $173 and an EV/EBITDA of 2.7 with zero bank debt and meaningful buyback optionality. Recent regulatory noise created a buying window. We outline a mid-term (45 trading days) trade plan: entry $173.30, target $235.00, stop $150.00, with clear catalysts and downside safeguards.
Obsidian Energy (OBE) has tightened its asset base and taken cash proceeds from a 2025 Cardium sale to reshape growth around Peace River. With market cap near $538M, a sub-1x P/B and deeply oversold technicals, we set a tactical long: enter at $8.00, stop $6.40, target $10.50 (mid-term) and $13.50 (longer-term).
Intel has run hard in 2026 on foundry momentum and AI optimism. That same AI cycle, by improving compute efficiency and consolidating spend into a narrower set of premium components, could blunt broader semiconductor unit growth and leave the stock vulnerable to a near-term re-rating. I recommend a tactical short with a mid-term horizon into the Ju…
Fannie Mae ($6.14) is behaving like a stock being prepped for a high-stakes privatization event: cleaner balance-sheet moves, product changes that broaden the buyer pool, and steady profitability. With a market cap of $7.11B and Q1 net income of $3.7B, the stock has material upside if policy execution stays intact. This is a mid-term swing trade to…
Cohu's recent pullback looks like an opportunity to add exposure to a company benefiting from AI-driven test equipment demand. Fundamentals show revenue momentum and improving gross margins guidance, while valuation already reflects a premium: market cap near $2.8B and EV/sales ~6x. This trade idea lays out an entry at $59.29, a stop at $52.00 and …
Mirum is trading near its 52-week high after broadening its liver-disease franchise via a sizable acquisition and continued product momentum. The fundamentals show revenue acceleration and improving margin trajectory, but the stock sits at a steep multiple and elevated RSI. This trade calls for a mid-term long (45 trading days) with a disciplined s…
UnitedHealth (UNH) has recovered sharply from its 2025 low and is trading near its 52-week high, but fundamentals - including $19.7B in free cash flow, an EV/Sales under 1.0 and a healthy balance sheet - support further upside if medical-cost trends stay contained and regulatory risk doesn't materialize. This idea recommends a patient, measured lon…
Ouster has the product wins and a manufacturing partner to scale REV8 sensors into automotive and robotics channels. The balance sheet and cash flow still lag, and the stock trades at a rich multiple, but a catalytic execution path argues for a tactical long over the next 180 trading days with tight risk control.
